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The immunogenicity of fractional (one-fifth, 0.1  mL) intra-
dermal doses of the inactivated poliovirus vaccine (ID fIPV) 
is positively correlated with the size of the intradermal fluid 
bleb. Training of vaccinators for campaign and routine ID fIPV 
administration should focus on generating an 8- to 10-mm bleb 
with each injection.
Clinical Trials Registration. NCT01847872
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The global effort to eradicate polio is now in its final endgame. 
Wild-type poliovirus type 2 was declared eradicated in September 
2015, and in April 2016 a synchronous switch from the use of the 
trivalent oral poliovirus vaccine (OPV) containing the type 1, 2, 
and 3 virus, to the bivalent format containing only the type 1 and 
3 virus, occurred globally [1]. The switch was to have been accom-
panied by the introduction of a routine dose of the (trivalent) 
inactivated poliovirus vaccine (IPV) in all countries using OPV 
only to mitigate against the risk of future type 2 disease in the 
event of a vaccine-derived poliovirus type 2 (VDPV2) outbreak; 
also, to enhance immunity against poliovirus types 1 and 3 [1]. 
However, requirements for IPV have outstripped manufacturing 
capacity and resulted in a vaccine shortage that has both delayed 
vaccine introduction and limited the vaccine stockpiles available 
for outbreak response. Consequently, in June 2016, following the 
detection of a VDPV2 during routine environmental surveillance 
in Telangana state in India, a campaign using fractional (one-fifth, 
0.1 mL) doses of IPV (fIPV) delivered by the intradermal (ID) 
route was undertaken and included a total of 311 064 children 
[2]. Certain Indian states and Sri Lanka have also introduced ID 
fIPV into their routine immunization schedules and, in response 
to the shortage, the World Health Organization (WHO) has now 
strongly recommended that ID fIPV be used universally, both in 
campaigns and routinely, advice which is expected to last until at 
least mid-2018 [3–5].
Whereas previous studies have confirmed the immunogenic-
ity of ID fIPV, the per-dose seroconversion rates and geometric 
mean neutralizing antibody titers are consistently lower than 
those generated by a full (0.5 mL) intramuscular (IM) dose of 
the same vaccine (Supplementary Table  1). This nested study 
provides definitive data on the effect of ID fluid bleb size on the 
immunogenicity of ID fIPV and should be used as a basis for 
current training and vaccination practice.
METHODS
Study Design
The study was nested in a clinical trial undertaken to exam-
ine the immunogenicity of ID fIPV and the use of disposable 
syringe jet injectors (DSJIs) to deliver IPV in 9- and 10-month-
old infants in The Gambia (NCT01847872) [6]. All infants had 
received at least 3 previous doses of the trivalent oral poliovi-
rus vaccine (tOPV) at least 28  days prior to enrollment (see 
Supplementary Table  2 for full eligibility criteria). The study 
was approved by The Gambia Government/MRC Joint Ethics 
Committee and was conducted according to the International 
Conference on Harmonization Good Clinical Practice and local 
ethical and regulatory guidelines. Full details of the enrollment 
procedures have previously been reported [6]. In brief, follow-
ing informed consent, infants were block-randomized into 1 of 
8 groups, of which 4 provided data for this study. Two groups 
received ID fIPV, the first using a needle and syringe (N&S) 
and the second using a DSJI (Tropis, PharmaJet). Two groups 
received a full IM dose of IPV using either a N&S or a DSJI 
(Stratis, PharmaJet). Immediately following each injection, any 
fluid lost onto the skin was absorbed with a Whatman filter 
paper disc and the ID bleb size was measured with a clear plastic 
ruler. The area of wetness on the filter paper was outlined and 
later compared in an observer-blinded fashion to a standard 
scale, allowing the volume of fluid loss to be quantified.
Serological Endpoint Measurement
A prevaccination serum sample was taken prior to IPV admin-
istration, and a postvaccination sample was taken 4–6 weeks 
later. There were no systematic differences in the timing of the 
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postvaccination sample between groups. Poliovirus serotypes 
1, 2, and 3 neutralizing antibody titers were assessed in a lab-
oratory observer–blinded fashion, as previously reported [7]. 
Serial 2-fold dilutions from a starting dilution of 1 in 8 were 
undertaken until an endpoint titer was obtained. Seropositivity 
was defined as reciprocal neutralizing antibody titers of ≥8. The 
rate of seroconversion (seronegative prevaccination to seropos-
itive postvaccination) and the number of infants who were sero-
positive at baseline and who had a 4-fold rise in antibody titers 
were calculated. These 2 groups were combined to provide a 
measure of the total response to the vaccine.
Statistical Analysis
Summary statistics were generated and the relationship between 
ID bleb size and cutaneous fluid loss and immunogenicity was 
assessed using Spearman correlation coefficient. The 95% 
confidence intervals (CIs) of the correlation coefficient were 
derived using the Fisher r-to-z transformation [8]. All analyses 
were done using Stata software (release 12.1).
RESULTS
Study Population, Baseline Seroprevalence, and Seroresponse
Seven hundred 9- and 10-month-old infants were recruited 
and randomized into 1 of the 4 groups and provided data for 
analysis in this study. The infants had received between 4 and 
7 (mean, 4.9) doses of tOPV prior to the current study—the 
last dose being at least 4 weeks prior to enrollment. Of the 700 
infants, 177 each received ID fIPV using a N&S and a DSJI. One 
hundred seventy-eight received a full IM dose of IPV using a 
N&S and 168 infants received a full IM dose using a DSJI.
The baseline poliovirus neutralizing antibody titer seroposi-
tivity rate was 85.9%–89.9% for poliovirus type 1, 96.1%–98.9% 
for poliovirus type 2, and 74.0%–82.7% for poliovirus type 
3.  Overall, 66.9% and 66.1% of infants had a poliovirus type 
1 immune response following IPV administration by the IM 
N&S and IM DSJI, respectively, compared to 55.9% and 43.5% 
for the same ID fIPV administration methods. The equivalent 
figures for poliovirus type 2 were 72.5% and 59.5% for the IM 
routes compared with 58.2% and 41.8% by the ID routes, and 
for poliovirus type 3, 82.6% and 81.0% by the IM routes com-
pared with 80.2% and 69.5% by the ID routes (Supplementary 
Table 3).
Effects of Bleb Size and Vaccine Loss on Intradermal Doses of the 
Inactivated Poliovirus Vaccine Immunogenicity
The median bleb size generated by the ID N&S was 8 mm with 
an interquartile range (IQR) of 7–8 mm, which was significantly 
larger (P < .0001) than the median size of 6 mm and interquar-
tile range of 5–7 mm generated by the ID DSJI (Table 1). There 
was a significant positive correlation between bleb size and 
the total immune response for all 3 poliovirus serotypes when 
combining data from the ID N&S and ID DSJI. The correlation 
remained for all 3 serotypes when examining administration 
by the ID DSJI and for serotype 1 when examining N&S-based 
administration (Table 1). A positive correlation was also noted 
when the relationship between bleb size and postvaccina-
tion antibody titers was examined (Supplementary Table  4). 
Furthermore, the immune responses to ID fIPV in infants with 
an 8- to 10-mm fluid bleb were comparable to those generated 
by a full IM dose of the same vaccine. Thus, 65.8% (95% CI, 
57.1%–74.5%; 75/114) of infants with a bleb size of 8–10 mm 
seroconverted or had a 4-fold rise in antibody titers to serotype 
1 compared with 66.5% (95% CI, 61.5%–71.4%; 230/346) of 
those who received a full IM dose of the vaccine. The equiva-
lent figures for serotype 2 were 58.8% (95% CI, 49.7%–67.8%; 
67/114) by the ID route compared with 66.2% (95% CI, 61.2%–
71.2%; 229/346) by the IM route and for serotype 3, 86.0% (95% 
CI, 79.6%–92.3%; 98/114) by the ID route compared with 81.8% 
(95% CI, 77.7%–85.9%; 283/346) by the IM route (Table 1 and 
Supplementary Table 3).
Of the 100-µL fractional dose volume, the median fluid loss 
with the N&S was between 2.5 µL and 5.0 µL, although >40.0 µL 
was lost in 6.3% of injections. The median fluid loss with the 
DSJI was between 5.0 μL and 10.0 µL, and 12.6% of injections 
resulted in >40  µL fluid loss. There was a significant inverse 
correlation between the volume of vaccine lost onto the skin 
at the time of injection and the size of the ID bleb generated 
(P  =  .001). This was maintained when data for N&S-based 
(P  =  .03), but not DSJI-based, ID fIPV administration were 
examined separately. The correlation coefficients were low in all 
cases, suggesting that, particularly in the case of the DSJI, vac-
cine injected deep to the dermis was also in part responsible for 
the smaller bleb sizes and hence immune responses reported in 
some cases (Supplementary Table 5).
There was a significant reduction in serotype 2 immuno-
genicity associated with increasing volumes of fluid lost onto 
the skin when the data for all ID vaccinations were analyzed 
(Supplementary Table 6). The volume of fluid loss had no effect 
on the immunogenicity IM IPV (data not shown).
DISCUSSION
This study demonstrates, to our knowledge for the first time, a 
significant positive correlation between the size of the ID fluid 
bleb generated at the time of ID fIPV administration and the 
subsequent immune response. The consistently lower immuno-
genicity of ID fIPV compared with a full IM dose of the same 
vaccine reported in previous studies (Supplementary Table 1) 
was largely overcome when a bleb size of 8–10 mm was gen-
erated. The findings are consistent with the one study that has 
examined the phenomenon previously, which reported a trend 
in the same direction but was inconclusive [9]. It should be 
noted that the trial was undertaken in tOPV-primed 9- and 
10-month-old infants and this should be considered in applying 
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the findings, although there is little reason to think that the 
trend reported would be restricted to this population.
The finding has important implications. First, it suggests that 
when training the large number of vaccinators required, based on 
recent WHO recommendations, to deliver ID fIPV in campaigns 
and routinely [5], the focus should be placed on maximizing the 
bleb size generated. Even a modest increase in the response rate in 
the population will reduce the compromise inherent in ID fIPV 
use. Second, the finding should guide the development of the next 
generation of needle-free and other devices designed to facilitate 
ID injections. Given the correlation, device optimization based 
in bleb measurement has the potential to reduce empirical mod-
ification and human testing. Finally, the finding may also have 
broader implications for the future delivery of other vaccines by 
the ID or cutaneous route, which warrant further assessment.
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